Barron's Interview With Biotech Analyst Tony Yao
7069 views
Rate Now: 1 2 3 4

average rating: 0.00 / 0 ratings
Created by barrons2
DESCRIPTION:

Date updated:04-05-2008

Wall Street was never too far away from Tony Yao's research lab at a Stanford University: One colleague started his own hedge fund and another went to work for fund manager Janus. While earning his M.D. and a Ph.D. in immunology, Yao tried to make ends meet as a research assistant. Then he discovered that evaluating disease therapies as a consultant for Silicon Valley's biotech firms paid much better. On graduation in 2002, Yao also joined Janus in Denver, where he covers emerging and mature biotech companies and specialty pharmaceuticals

symbol name last price % change open
  • +
  • CELG
    Celgene Corporati
  • $54.77
  • -0.71%
  • $N/A

Q: Let's talk about stocks. What should we be looking for? A: Celgene is in the early innings. It's probably one of the highest growers on both the top and bottom line of a company of its size in its category. I think it is worth between $80 and $85, and it's at $64 now.

People owning CELG also tend to own: GTIACIRADSTXNVARASHBNI

TheStreet.com Rating: C+ What is this?

  • +
  • ACL
    Alcon Inc
  • $156.11
  • +0.20%
  • $155.80

Q: You like Alcon. A: My Alcon price target will go to $176 with my 10% discount rate for 2009. So I get $160 to $165, and the stock is at $145.

People owning ACL also tend to own: AVPCQBMXIMQCOMSAFMSNDASTJ

TheStreet.com Rating: B What is this?

  • +
  • GILD
    Gilead Sciences
  • $46.09
  • -0.63%
  • $46.31

Q: So what's the stock worth? A: My price target is 60, which you might consider fairly modest. For our firm, the ability to put large amounts of money in a good-visibility, market-leading stock with accelerating growth in these types of situations is a good deal.

People owning GILD also tend to own: ACLALXNBMRNCELGCVHCVSESRX

TheStreet.com Rating: A- What is this?

  • +
  • AGN
    Allergan Inc
  • $58.17
  • +0.24%
  • $57.91

Q: What's your next pick? A: The last part is breast implants, 8% of sales, which is probably the most likely to be impacted by the economy. They have been growing market share against their single U.S. competitor, Mentor (MNT). The stock is at 58, but I think it's worth 75 on a discounted cash-flow basis. Like with Allergan, the economic impact is not nearly as significant as people think. Based on consensus numbers for '08, it's trading at 22.5 times, which isn't that expensive.

People owning AGN also tend to own: ALKBABKCCACMCSAERIE

TheStreet.com Rating: B What is this?

  • +
  • KVA
    K V Pharma Cl A
  • $3.03
  • -5.02%
  • $3.19

Q: What else? A: The company is small. They have a sensible brand business, too, which means they generate more sustainable earnings and revenues. They have actually built a very nice women's health business consisting of prenatal vitamins, iron supplements, anti-fungal/anti-bacterial treatments, and now hormone replacement. Evamist is their new spray estrogen. Their generic business runs gross margins of more than 55%, which is very high. The stock is now around $25 and I think it's worth $35.

People owning KVA also tend to own: ALSKHGTMRKOMEOTTRPGHQLGC

TheStreet.com Rating: No Rating What is this?

  • +
  • AMGN
    Amgen Inc.
  • $57.46
  • -0.38%
  • $57.47

Q: So what do you think of Amgen, where people have waited for a turnaround for what seems like forever? A: Another analyst covers Amgen. The near-term prospects for the company are filled with uncertainty. Interestingly, Gilead is now bigger than Amgen. Amgen faces ongoing litigation with Roche (ROG.Switzerland), uncertainty regarding FDA changes to the ESA [erythropoiesis-stimulating agents] labels, and confusion regarding its safety profile. However, the Street may be pricing in a worst-case scenario, which might provide upside to long-term investors.

People owning AMGN also tend to own: APABACCCOPCVXDOWDRE

TheStreet.com Rating: B What is this?

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Must-See Charts: Ralcorp, Del Mo...

By Jonas Elmerraji Posted on Feb. 9, 2010 With stocks continuing to underwhelm in yesterday’s trading session, the attention is turning toward trading. After all, tec...

02.09.10 | 12:06 PM
This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Feb. 8, 2010 Good Buys For Bad Times: This Barron’s article says with the U.S. economy expected to grow by only 3% in 2010, investors shou...

02.08.10 | 16:28 PM
Cramer's Take on Headline Stocks...

Posted on Feb. 8, 2010 Finance Professor Scott Rothbort will be answering questions on Stockpickr Answers on Monday, Feb. 8. Ask away! Regardless of why a stock is in...

02.08.10 | 14:45 PM
Rocket Stocks for the Week

By Jonas Elmerraji Posted on Feb. 8, 2010 Finance Professor Scott Rothbort will be answering questions on Stockpickr Answers on Monday, Feb. 8. Ask away! Investor an...

02.08.10 | 08:39 AM
more articles
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Everything Goldman Sachs. The in...
01.11.10 | 12:54 PM From author DogBones
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
Here is a Hidden Gem - FLL
01.15.10 | 18:19 PM From author adrianpena
more forums
today 's lists
Top Open-Market Insider Sales

Below is the list of the top open-market insider sales filed at the SEC on Feb. 8, 2010. more

TheStreet Ratings' Upgrades

TheStreet Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first&quo... more

Cramer's Lightning Round

These are the stocks from Jim Cramer's Feb. 8 Lightning Round. We list the stocks on which he is BULLISH and BEARISH.... more